New Zealand Clinical Research (PRIVATE.NZCR)

Overall impact
C (56)

Commentary

New Zealand Clinical Research is an average overall performer. With a 'C' rating of 55.9 for overall impact (55th percentile compared to all companies), New Zealand Clinical Research ranks 38th out of 52 industry peers, behind Agilent, LGC Group, Pace Analytical Services and 34 others, and ahead of Eversana, Flourish Research, Ascential Technologies and 11 others. On top material causes for New Zealand Clinical Research's industry (Life Sciences Tools & Services), New Zealand Clinical Research performs well in Child and Maternal Health (95.2 score), Child and Maternal Health (95.2), Child and Maternal Health (95.2) and 3 other causes where it received an 'A' score and performs poorly in Humane Treatment of Animals (1.8 score), Fair Labor Practices (26.5), Reduced Inequality (31.8) and 4 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.NZCR
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
232
Sector
Health Care
Industry
Life Sciences Tools & Services
Sub-industry
Life Sciences Tools & Services
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
New Zealand
Share classes
PRIVATE.NZCR
Description
Provider of clinical research services intended to conduct complex early-phase research in healthy participant and patient populations. The company provides early-stage clinical trials to global pharmaceutical and biotechnology companies, ensuring organizations with completion of a wide range of research projects on time and within budget.
Material causes
Ethos considers the following causes material for New Zealand Clinical Research, based on its industry sub-industry Life Sciences Tools & Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.